Skip to main content

Crohn's & Colitis
blogs, news & research

Research

IBD, steroid use increases influenza risk


IBD, steroid use increases influenza risk

Patients with inflammatory bowel disease have a higher risk for influenza and are more likely to be hospitalized because of it, according to research published in Inflammatory Bowel Diseases.

Andrew Tinsley, MD, of the division of gastroenterology and hepatology at The Pennsylvania State University Hershey Medical Center, and colleagues wrote that their findings highlight the importance of vaccinating patients with IBD, particularly because immunization rates are generally low in that population.

“Misunderstanding about appropriateness and timing of various vaccinations, especially for those on immunosuppressive agents, appears to be high,” they wrote. “Rates of influenza vaccination in IBD patients have been shown to be very low, highlighting the need for improved efforts by gastrointestinal providers to ensure that patients are appropriately protected whenever possible.”

Researchers analyzed data from the MarketScan Database on 140,480 patients with and without IBD from 2008 to 2011. They compared incidence rates for influence between both groups and conducted a nested case-control study to assess any potential independent effect of IBD medications on influenza risk. The study included 68,586 patients with ulcerative colitis and 71,894 patients with Crohn’s disease. They noted that reliable information regarding vaccination status was not included in this data.

In the IBD population, Tinsley and colleagues identified 2,963 patients with influenza and determined an annual incidence rate of 709.5 per 100,000 per-years. There were 1,941 patients with influenza in the non-IBD population and an annual incidence rate of 459.7 per 100,00 person-years. Patients with CD had a higher annual incidence rate than patients with UC (766.2 vs 650.2 per 100,000 person-years).

Investigators determined that patients with IBD had an increased influenza risk compared with patients without IBD (incidence rate ratio = 1.54; 95% CI, 1.46–1.63), as well as a higher rate of hospitalizations (5.4% vs. 1.85%; P < .001).

Read full article on www.healio.com

Posted on: July 20 2018

Leave a comment

Your email address will not be published. Required fields are marked *

Good article. I certainly appreciate this site. Continue the good work!

I was very interested in the article "Good Vs bad bacteria - the bugs responsible for Crohn's disease". I was diagnosed with IBD 6 months ago and after a very bad reaction to Pentasa (but unproven) I was told to wait and try again when the symptoms peaked again. However, I started taking Probiotics each day and (touch wood) I have been in remission for 5 months, with high hopes. I am very interested in the research in this field.

My 16 year old daughter was diagnosed with UC in July 2016 and after 4 flare ups within 12 months and trying different medications, she was prescribed infliximab. This has been the miracle medication for her and am so thankful that she has been able to return to a "relatively normal life", enjoying school and her passion for sports again (bar 8 weekly visits to PMH for inflixmab infusions, routine colonoscopies and mezzaline daily). I had very little knowledge of UC and autoimmunie disease for that matter; and was shellshocked at how debilitating it can be. We are so grateful to have a wonderful gastro and medical team supporting my daughter and of course the impact that inflixmab has had; however know it is still early days and don't want to take anything for granted.


About the author


Crohns & Colitis